

[Look Up Full Text](#)[Find PDF](#)[Export...](#)[Add to Marked List](#)

◀ 1 of 1 ▶

## Cardiovascular Outcomes and the Use of Oral Antidiabetic Drugs: A Review of Current Evidence from Observational Studies

By: Elnaem, MH (Elnaem, M. H.)<sup>[1,2]</sup>; Azam, FM (Azam, Mohd F.)<sup>[1]</sup>; Akkawi, ME (Akkawi, M. E.)<sup>[1,2]</sup>

IIUM MEDICAL JOURNAL MALAYSIA

Volume: 19 Issue: 3 Pages: 100-110

Published: OCT 2020

Document Type: Review

### Abstract

Type 2 diabetes mellitus (T2DM) is a major global disease burden that affects millions of people worldwide. The disease is well known to predispose patients to a wide range of macro- and microvascular complications. Cardiovascular complications are common macrovascular consequences among patients with T2DM. The primary goal of T2DM management is to achieve proper glycaemic control that helps to avoid or delay the incidence of disease complications. T2DM management involves the utilisation of oral antidiabetic medications and injectables, including insulin. Hence, we conducted this work to discuss and summarise the cardiovascular outcomes associated with the oral antidiabetic pharmacotherapy prescribed for patients with T2DM. The agents involved were metformin, sulfonylurea, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors. We decided to focus on the findings reported from observational studies published between 2009 to 2019 to provide an updated and more realistic insight on these cardiovascular outcomes associated with the oral antidiabetic drugs in the usual clinical practice.

### Keywords

Author Keywords: cardiovascular outcomes; oral antidiabetic drugs; oral hypoglycaemic agents

KeyWords Plus: GLUCOSE COTRANSPORTER-2 INHIBITORS; TYPE-2 DIABETES-MELLITUS; HEART-FAILURE; METFORMIN; RISK; MORTALITY; SULFONYLUREA; ACARBOSE; INSULIN; DISEASE

### Author Information

#### Reprint Address:

International Islamic University Malaysia Int Islamic Univ Malaysia, Dept Pharm Practice, Kulliyah Pharm, Kuantan 25200, Pahang, Malaysia.

Corresponding Address: Elnaem, MH (corresponding author)

+ Int Islamic Univ Malaysia, Dept Pharm Practice, Kulliyah Pharm, Kuantan 25200, Pahang, Malaysia.

#### Addresses:

+ [ 1 ] Int Islamic Univ Malaysia, Dept Pharm Practice, Kulliyah Pharm, Kuantan 25200, Pahang, Malaysia

+ [ 2 ] Int Islamic Univ Malaysia, Qual Use Med Res Grp, Kulliyah Pharm, Kuantan, Pahang, Malaysia

E-mail Addresses: [drmelnaem@iium.edu.my](mailto:drmelnaem@iium.edu.my)

### Funding

Funding Agency	Grant Number
Research Management Center of the International Islamic University Malaysia	RIGS17-122-0697

[View funding text](#)

### Publisher

INT ISLAMIC UNIV MALAYSIA, KULLIYAH MEDICINE, JALAN SULTAN AHMAD SHAH, KUANTAN PAHAN, 25200, MALAYSIA

### Citation Network

In Web of Science Core Collection

0

Times Cited

[Create Citation Alert](#)

40

Cited References

[View Related Records](#)

### Use in Web of Science

Web of Science Usage Count

0

Last 180 Days

0

Since 2013

[Learn more](#)

This record is from:

Web of Science Core Collection

- Emerging Sources Citation Index

#### Suggest a correction

If you would like to improve the quality of the data in this record, please [suggest a correction](#).

**Categories / Classification**

Research Areas: General &amp; Internal Medicine

Web of Science Categories: Medicine, General &amp; Internal

**See more data fields**

◀ 1 of 1 ▶

**Cited References: 40**Showing 30 of 40 [View All in Cited References page](#)*(from Web of Science Core Collection)*

1. **(2) Classification and diagnosis of diabetes.** Times Cited: **1,346**  
Corporate Author(s): American Diabetes Association  
Diabetes care Volume: 38 Suppl Pages: S8-S16 Published: 2015 -Jan
2. **SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL** Times Cited: **45**  
By: Cavender, Matthew A.; Norhammar, Anna; Birkeland, Kare I.; et al.  
Group Author(s): CVD-REAL Investigators Study Grp  
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Volume: 71 Issue: 22 Pages: 2497-2506 Published: JUN 5 2018
3. **Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study** Times Cited: **20**  
By: Chan, Cheng-Wei; Yu, Chu-Leng; Lin, Jiunn-Cherng; et al.  
CARDIOVASCULAR DIABETOLOGY Volume: 17 Article Number: 20 Published: JAN 24 2018
4. **Cardiovascular Risk Associated With Acarbose Versus Metformin as the First-Line Treatment in Patients With Type 2 Diabetes: A Nationwide Cohort Study** Times Cited: **24**  
By: Chang, Chia-Hsuin; Chang, Yi-Cheng; Lin, Jou-Wei; et al.  
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Volume: 100 Issue: 3 Pages: 1121-1129 Published: MAR 2015
5. **Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study** Times Cited: **15**  
By: Chen, Jui-Ming; Chang, Cheng-Wei; Lin, Ying-Chieh; et al.  
JOURNAL OF DIABETES RESEARCH Volume: 2014 Article Number: 812628 Published: 2014
6. **Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study** Times Cited: **1**  
By: Chin, HJ; Nam, JH; Lee, EK; et al.  
Med Volume: 96 Issue: 25 Pages: 1-8 Published: 2017  
[\[Show additional data\]](#)
7. **Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy** Times Cited: **3**  
By: Cho, Eun Hyung; Park, Se-Jun; Han, Seongwook; et al.  
JOURNAL OF DIABETES RESEARCH Volume: 2018 Article Number: 6807219 Published: 2018
8. **The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies** Times Cited: **4**  
By: Dhindsa, Devinder S.; Sandesara, Pratik B.; Shapiro, Michael D.  
FRONTIERS IN CARDIOVASCULAR MEDICINE Volume: 5 Article Number: 160 Published: NOV 13 2018
9. **Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study** Times Cited: **1**  
By: Douros, A; DellAniello, S; Yu, OHY; et al.  
BMJ. Volume: 362 Published: 2018  
[\[Show additional data\]](#)
10. **Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists** Times Cited: **1**  
By: Elnaem, MH; Cheema, E.